Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07284472
PHASE2/PHASE3

Safety and Efficacy of EXV-802 and EXV-801 in the Treatment of Agitation in Alzheimer's Disease Dementia

Sponsor: Exciva GmbH

View on ClinicalTrials.gov

Summary

The goal of this clinical trial is to evaluate the safety and efficacy of EXV-802 and EXV-801 in treatment of agitation in participants with Alzheimer's Disease dementia.

Official title: Phase 2/3, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of EXV-802 and EXV-801 in the Treatment of Agitation in Participants With Alzheimer's Disease Dementia

Key Details

Gender

All

Age Range

55 Years - 90 Years

Study Type

INTERVENTIONAL

Enrollment

300

Start Date

2026-02-02

Completion Date

2029-02

Last Updated

2026-03-04

Healthy Volunteers

No

Interventions

DRUG

EXV-802

Specified dose twice daily

DRUG

Placebo

Specified dose twice daily

DRUG

EXV-801

Specified dose twice daily

Locations (13)

Esperanza Clinical

Murrieta, California, United States

Josephson Wallack Munshower Neurology PC

Indianapolis, Indiana, United States

Precise Research Centers

Flowood, Mississippi, United States

Integrative Clinical Trials

Brooklyn, New York, United States

Manhattan Behavioral Medicine

New York, New York, United States

Insight Clinical Trials

Independence, Ohio, United States

Oregon Health & Science University

Portland, Oregon, United States

The Memory Clinic

Bennington, Vermont, United States

Sunnybrook Health Sciences Centre

North York, Ontario, Canada

Baycrest Centre for Geriatric Care

North York, Ontario, Canada

Kawartha Centre

Peterborough, Ontario, Canada

Ontario Shores Centre for Mental Health Sciences

Whitby, Ontario, Canada

Scottish Brain Sciences

Edinburgh, Midlothian, United Kingdom